Melanoma therapy produces positive mid-stage data
Researchers for GlaxoSmithKline and Synta Pharmaceuticals say a mid-stage study of elesclomol produced "statistically significant" data on progression-free survival of patients with metastatic melanoma.
"These data, combined with earlier clinical and pre-clinical data we have presented for elesclomol, support our belief that oxidative stress induction is a promising new approach to cancer therapy in melanoma and, potentially, other cancer types," said Eric Jacobson, M.D., Synta's CMO.
- here's the press release
- read the AFX report
Related Articles:
Synta outlines cash flow from Glaxo pact
Synta scores $1.1B deal with GSK
Synta therapy slows spread of melanoma
Synta gets fast track for cancer therapy
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
